The disease itself does not affect the fertility of patients, but the drugs used in the treatment of patients with dry syndrome may have teratogenic effects, and the combination of dry syndrome with positive anticardiolipin antibodies will increase the chances of miscarriage, preterm delivery and fetal malformation. Dry syndrome mainly occurs in female patients between 30 and 60 years old and mainly involves salivary glands, lacrimal glands and other exocrine glands, and if the disease involves connective tissues, it may lead to symptoms of bones, skin, internal organs and other multi-systems and multi-viscera. Generally speaking, dry syndrome does not affect the fertility of the patients, but the disease can not be cured, so it usually requires long-term drug treatment. Commonly used drugs in the drug treatment of dry syndrome include antimalarials such as chloroquine, glucocorticosteroids such as prednisone, immunosuppressants such as methotrexate and leflunomide, etc. Among them, methotrexate, leflunomide and other drugs have teratogenicity, so if the condition of the patient with dry syndrome is still under control and there is a need for reproduction, the patient can be prepared for pregnancy under the guidance of a physician. The combination of dry syndrome and anticardiolipin antibody positive patients may also increase the chance of miscarriage and preterm delivery. It is recommended that patients with dry syndrome who have the need to have children go to the rheumatology and immunology department of regular hospitals for detailed consultation.